Maria Saigí

908 total citations
24 papers, 380 citations indexed

About

Maria Saigí is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Maria Saigí has authored 24 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology. Recurrent topics in Maria Saigí's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Research Studies (5 papers) and Immunotherapy and Immune Responses (5 papers). Maria Saigí is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Research Studies (5 papers) and Immunotherapy and Immune Responses (5 papers). Maria Saigí collaborates with scholars based in Spain, France and United States. Maria Saigí's co-authors include Montse Sánchez‐Céspedes, Ernest Nadal, Juan J. Alburquerque-Béjar, Eva Pros, Octavio A. Romero, Élisabeth Brambilla, Anna Esteve‐Codina, Manel Esteller, Antoni Rosell and Enric Carcereny and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Maria Saigí

21 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Saigí Spain	10	203	172	142	104	66	24	380
Caroline Hego France	7	131 0.6×	156 0.9×	77 0.5×	178 1.7×	112 1.7×	8	394
Hailing Jin United States	10	183 0.9×	103 0.6×	118 0.8×	100 1.0×	26 0.4×	11	340
Zhiying Zheng China	8	235 1.2×	143 0.8×	164 1.2×	176 1.7×	146 2.2×	15	439
Dagui Lin China	8	130 0.6×	252 1.5×	203 1.4×	126 1.2×	112 1.7×	18	428
Nobuhiko Nishijima Japan	8	133 0.7×	110 0.6×	143 1.0×	79 0.8×	28 0.4×	15	302
Chie Soeno Japan	10	326 1.6×	124 0.7×	104 0.7×	211 2.0×	31 0.5×	13	454
Mark P. Roberto United States	4	100 0.5×	112 0.7×	110 0.8×	54 0.5×	61 0.9×	4	285
M. D’Arcangelo Italy	12	119 0.6×	200 1.2×	196 1.4×	79 0.8×	41 0.6×	31	360
Jin‐Ling Duan China	13	265 1.3×	105 0.6×	93 0.7×	139 1.3×	52 0.8×	29	407
Yuto Yasuda Japan	10	121 0.6×	221 1.3×	172 1.2×	62 0.6×	59 0.9×	35	346

Countries citing papers authored by Maria Saigí

Since Specialization

Citations

This map shows the geographic impact of Maria Saigí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Saigí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Saigí more than expected).

Fields of papers citing papers by Maria Saigí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Saigí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Saigí. The network helps show where Maria Saigí may publish in the future.

Co-authorship network of co-authors of Maria Saigí

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Saigí. A scholar is included among the top collaborators of Maria Saigí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Saigí. Maria Saigí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nadal, Ernest, Paloma Martín-Martorell, José Carlos Benítez, et al.. (2025). Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Lung Cancer. 203. 108545–108545.

Rosell, Antoni, Maria Saigí, Jordi Bechini, et al.. (2025). A cost minimization analysis of the implementation of the international lung screening trial in Catalonia (Spain). BMC Health Services Research. 25(1). 1001–1001.

Saigí, Maria, José Luís Mate, Enric Carcereny, et al.. (2024). HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 189. 107502–107502. 2 indexed citations

Carcereny, Enric, Maria Saigí, Anna Esteve, et al.. (2023). P1.21-04 Role of HLA-I as a Molecular Prognostic Factor for Long Term Responders in Non-small Cell Lung Cancer Patients Treated with Immunotherapy. Journal of Thoracic Oncology. 18(11). S235–S235. 1 indexed citations

Cucurull, Marc, Carolina Sanz, Enric Carcereny, et al.. (2023). Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C. Frontiers in Oncology. 13. 1239000–1239000. 2 indexed citations

Alburquerque-Béjar, Juan J., Maria Saigí, Antonio Gómez, et al.. (2023). MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. Cell Reports Medicine. 4(4). 101006–101006. 19 indexed citations

Rubió‐Casadevall, Jordi, Alicia Lozano, María Buxó, et al.. (2023). Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population. Clinical & Translational Oncology. 25(8). 2384–2392. 1 indexed citations

Cucurull, Marc, Montse Sánchez‐Céspedes, Cinta Hierro, et al.. (2022). Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies. Frontiers in Oncology. 11. 793121–793121. 21 indexed citations

Saigí, Maria, Enric Carcereny, Teresa Morán, et al.. (2022). Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer. Cancer Treatment Reviews. 109. 102430–102430. 6 indexed citations

10.

Quirant‐Sánchez, Bibiana, Eudald Felip, Maria Saigí, et al.. (2022). OA06.04 Immune Response after SARS-CoV-2 Vaccination in Lung Cancer Patients. Update of the Covid Lung Vaccine Cohort. Journal of Thoracic Oncology. 17(9). S18–S18. 1 indexed citations

11.

Romero, Octavio A., Juan J. Alburquerque-Béjar, Antonio Gómez, et al.. (2021). SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications. 12(1). 4319–4319. 36 indexed citations

12.

Plaja, Andrea, Teresa Morán, Enric Carcereny, et al.. (2021). 1658P Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED). Annals of Oncology. 32. S1168–S1168. 2 indexed citations

13.

Doménech, Marta, Ana M Muñoz‐Mármol, José Luís Mate, et al.. (2021). Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small-cell lung cancer and no other actionable oncogenic driver. Oncotarget. 12(18). 1802–1810. 12 indexed citations

14.

Rullan, Antonio, Maria Saigí, Inmaculada Peiró, et al.. (2019). Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. BMC Cancer. 19(1). 165–165. 26 indexed citations

15.

Saigí, Maria, Juan J. Alburquerque-Béjar, & Montse Sánchez‐Céspedes. (2019). Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. Oncogene. 38(31). 5921–5932. 25 indexed citations

16.

Coloma, Carmen Salvador, Maria Saigí, Robert Díaz Beveridge, et al.. (2019). <p>Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas</p>. OncoTargets and Therapy. Volume 12. 9265–9275. 5 indexed citations

17.

Saigí, Maria, Juan J. Alburquerque-Béjar, Carolina Pereira, et al.. (2018). MET -Oncogenic and JAK2 -Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. Clinical Cancer Research. 24(18). 4579–4587. 75 indexed citations

18.

Saigí, Maria, Anne McLeer‐Florin, Eva Pros, et al.. (2017). Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer. Clinical & Translational Oncology. 20(7). 881–888. 15 indexed citations

19.

Saigí, Maria, Marc Oliva, Luisa Aliste, et al.. (2017). Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. PLoS ONE. 12(9). e0184737–e0184737. 6 indexed citations

20.

Díaz‐Lagares, Ángel, Jesús Méndez‐González, David Hervás, et al.. (2016). A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. Clinical Cancer Research. 22(13). 3361–3371. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact